샘플 요청 목록

 카트 문의
시장보고서
상품코드
1774923

세계의 원내감염 진단 시장

Hospital Acquired Infections Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 469 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 원내감염 진단 시장은 2030년까지 88억 달러에 이를 전망

2024년에 83억 달러로 추정되는 원내감염 진단 세계 시장은 2024-2030년간 CAGR 1.0%로 성장하여 2030년에는 88억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 소모품은 CAGR 1.3%를 나타내고, 분석 기간 종료시에는 58억 달러에 이를 것으로 예측됩니다. 기기 부문의 성장률은 분석 기간중 CAGR 0.5%로 추정됩니다.

미국 시장은 23억 달러로 추정, 중국은 CAGR 2.1%로 성장 예측

미국의 원내감염 진단 시장은 2024년에 23억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 16억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 2.1%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 0.3%와 0.9%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 0.5%로 성장할 전망입니다.

세계 원내 감염 진단 시장 - 주요 동향 및 촉진요인 정리

현대 의료 시스템에서 원내 감염 진단이 중요한 이유는 무엇인가?

원내 감염(HAI)은 원내 감염으로도 알려져 있으며, 환자의 이환율, 입원 기간 및 치료 비용을 증가시켜 전 세계 의료 시스템에 큰 부담을 주고 있습니다. 카테터 관련 요로감염(CAUTI), 중심정맥관 관련 혈류감염(CLABSI), 수술부위감염(SSI), 인공호흡기 관련 폐렴(VAP)과 같은 감염은 병원 전체, 특히 중환자실(ICU)에서 유행하고 있습니다. 전 세계적으로 항균제 내성(AMR)이 증가함에 따라 HAI의 적시 식별과 표적 치료는 환자 예후와 병원 성과 지표에 매우 중요해지고 있습니다. 진단약은 원인 병원균을 신속하게 검출하고 항균제 감수성을 판단하는 최전방 역할을 수행하여 임상의가 효과적인 개입을 시작할 수 있게 함과 동시에 광범위 항생제 오남용을 최소화할 수 있습니다. 규제적 의무와 상환 모델로 인해 감염 예방 및 관리(IPC) 프로토콜의 채택이 증가하고 있으며, 진단의 역할은 반응적인 것에서 적극적인 감염 억제에 대한 역할이 증가하고 있습니다. 병원은 인증을 유지하고, 처벌을 피하고, 의료 관련 비용을 절감해야 한다는 압박에 직면하고 있으며, HAI 진단은 위험 감소, 발병 감시, 의료 질 향상에 필수적인 도구로 부상하고 있습니다.

진단 기술의 발전이 HAI 검출 및 임상 대응을 어떻게 가속화하고 있는가?

기술 혁신은 배양 기반 진단에서 원내 감염을 위한 신속, 현장 진단 및 다중 분자 솔루션으로의 전환을 촉진하고 있습니다. 기존의 미생물 검사는 병원균의 확실한 동정을 위한 기준이지만, 실시간 중합효소연쇄반응(RT-PCR), 핵산증폭검사(NAAT), 루프매개 등온증폭법(LAMP)에 의해 보완되고 있으며, 더 빠른 처리 시간을 위해 많은 경우 대체되고 있습니다. 하고 있습니다. 이러한 분자 분석은 높은 민감도와 특이성을 제공하며, 배양에 필요한 며칠의 기간과 비교하여 종종 몇 시간 이내에 결과를 제공합니다. 미생물 식별과 민감도 프로파일링을 통합한 자동 혈액 배양 시스템은 패혈증 및 혈류 감염의 진단에 점점 더 많이 사용되고 있습니다. 질량 분석 플랫폼, 특히 매트릭스 지원 레이저 탈이온화 이온화 비행시간 분석(MALDI-TOF)은 실험실 운영 비용을 줄이면서 생물체 식별을 가속화하고 있습니다. 차세대 염기서열 분석기(NGS)는 감염 발생을 추적하고 내성 유전자를 특성화할 수 있는 강력한 도구로 부상하고 있습니다. 또한, 바이오센서, 마이크로유체공학, 랩온칩 기술의 발전으로 실시간 데이터 출력을 통한 병상 진단이 가능해졌으며, AI 기반 분석과 병원 전체 감시 플랫폼의 통합으로 감염 추적, 예측 모델링, 임상 의사결정 지원을 강화할 수 있게 되었습니다. 의사결정 지원을 강화하고 있습니다. 이러한 혁신은 진단의 속도와 정확성을 향상시킬 뿐만 아니라, 조기 격리와 표적 치료를 촉진하여 HAI의 확산을 억제하고 임상 결과를 개선하고 있습니다.

HAI 대응을 위한 진단약 도입의 촉매제가 되고 있는 헬스케어의 역동성과 규제 압력은 무엇인가?

다제내성균(MDRO) 증가, 침습적 기구 사용 증가, 복잡한 합병증을 동반한 고령화로 인해 HAI의 위험 프로파일이 확대되고 있으며, 이에 따라 강력한 진단 능력에 대한 필요성이 증가하고 있습니다. 병원은 질병통제예방센터(CDC), 세계보건기구(WHO), 지역 보건당국 등 규제기관으로부터 HAI 발생률을 실시간으로 정확하게 모니터링하고 보고할 것을 점점 더 엄격하게 요구받고 있습니다. 메디케어 및 메디케이드 서비스의 성과 보상형 의료 모델과 페널티 구조는 병원에 HAI 발생률을 낮추거나 금전적 영향을 받을 위험을 감수할 수 있는 인센티브를 제공합니다. Joint Commission의 국가 환자안전목표(National Patient Safety Goals)와 같은 인증기관 및 감염관리 기준은 진단 규정 준수를 핵심 요건으로 강화하고 있으며, 코로나19 사태는 의료 환경에서 교차 감염을 예방하기 위한 신속한 진단의 중요성을 강조하고 있습니다. 의료 환경에서 교차 감염을 예방하기 위한 신속한 진단의 중요성을 더욱 부각시켰습니다. 의료진에 대한 인식이 높아지고 IPC 교육이 실시되면서 조기 발견과 항균제 관리를 지원하는 통합 진단 솔루션에 대한 수요도 증가하고 있습니다. 인력 부족과 업무량 압박에 직면한 병원 실험실은 처리 시간을 유지하고 워크플로우 효율성을 개선하기 위해 자동화 및 고처리량 진단 플랫폼에 투자하고 있습니다. 이러한 움직임은 전 세계 의료시설에서 진단이 감염 관리 생태계의 필수적인 요소로 자리 잡고 있음을 보여줍니다.

지역과 이용 사례를 막론하고 원내 감염 진단 시장의 성장을 주도하는 요인은 무엇인가?

원내 감염 진단 시장의 성장은 감염률 증가, 기술 혁신, 진화하는 의료 책임 기준의 조합에 의해 이루어지고 있습니다. 고소득 국가들은 엄격한 감시 요건을 충족하고 병원의 책임을 줄이기 위해 첨단 분자 및 디지털 진단 플랫폼에 투자하고 있습니다. 신흥 경제국에서는 급속한 도시화, 의료 접근성 확대, IPC 프로그램에 대한 국제적인 자금 지원으로 인해 자원이 제한된 환경에 맞게 조정된 저렴한 가격의 신속한 진단 도구의 도입이 가속화되고 있습니다. 특히 종양학, 장기이식, 신생아 의료, 수술, 중환자실, 면역결핍 환자군의 확대는 HAI의 조기 및 정확한 진단에 대한 수요를 증가시키고 있습니다. 분산형 진단, 현장 검사, 재택치료에 대한 추세는 소형, 자동화된, 사용하기 쉬운 진단 솔루션의 새로운 응용 기회를 창출하고 있습니다. 민관 파트너십, 유리한 상환 구조, 항균제 내성 대응을 위한 정부의 이니셔티브는 시장의 모멘텀을 더욱 가속화하고 있습니다. 이러한 요인들이 복합적으로 작용하여 빠르게 변화하는 세계 보건 환경에서 보다 안전한 의료 서비스 제공, 탁월한 운영 및 감염 예방을 실현하는 중요한 수단으로 시장 상황을 주도하고 있습니다.

부문

제품(소모품, 기기), 검사(분자 검사, 기존 검사), 제품 유형(혈액검사, 소변검사), 감염(요로 결석, 폐렴, 수술 부위 감염, 혈류감염, 기타)

조사 대상 기업 예

  • Abbott Laboratories
  • Bayer AG
  • Beckman Coulter(a Danaher Company)
  • Becton, Dickinson and Company(BD)
  • bioMerieux
  • Bio-Rad Laboratories, Inc.
  • Cepheid(a Danaher Company)
  • Danaher Corporation
  • Ecolab Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenMark Diagnostics(acquired by Roche)
  • Hologic, Inc.
  • Johnson & Johnson
  • Luminex Corporation
  • Merck KGaA
  • Pfizer Inc.
  • QIAGEN N.V.
  • Siemens Healthineers
  • STERIS plc
  • Thermo Fisher Scientific Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.31

Global Hospital Acquired Infections Diagnostics Market to Reach US$8.8 Billion by 2030

The global market for Hospital Acquired Infections Diagnostics estimated at US$8.3 Billion in the year 2024, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 1.0% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 1.3% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 0.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 2.1% CAGR

The Hospital Acquired Infections Diagnostics market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 2.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.3% and 0.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.5% CAGR.

Global Hospital Acquired Infections Diagnostics Market - Key Trends & Drivers Summarized

Why Are Hospital Acquired Infections Diagnostics Becoming a Priority in Modern Healthcare Systems?

Hospital acquired infections (HAIs), also known as nosocomial infections, continue to pose a significant burden on global healthcare systems-driving up patient morbidity, length of stay, and treatment costs. Infections such as catheter-associated urinary tract infections (CAUTIs), central line-associated bloodstream infections (CLABSIs), surgical site infections (SSIs), and ventilator-associated pneumonia (VAP) are prevalent across hospitals, especially in intensive care units (ICUs). As antimicrobial resistance (AMR) escalates globally, timely identification and targeted treatment of HAIs have become critical to patient outcomes and hospital performance metrics. Diagnostics play a frontline role in rapidly detecting the causative pathogens and determining their antimicrobial susceptibility, enabling clinicians to initiate effective interventions while minimizing the misuse of broad-spectrum antibiotics. The rising adoption of infection prevention and control (IPC) protocols, driven by regulatory mandates and reimbursement models, is elevating the role of diagnostics from reactive to proactive infection containment. With hospitals facing increasing pressure to maintain accreditation, avoid penalties, and reduce healthcare-associated costs, HAI diagnostics are emerging as essential tools in risk mitigation, outbreak surveillance, and quality of care improvement.

How Are Advancements in Diagnostic Technologies Accelerating HAI Detection and Clinical Response?

Technological innovations are driving a shift from culture-based diagnostics to rapid, point-of-care, and multiplex molecular solutions for hospital acquired infections. Traditional microbiology, while still a benchmark for definitive pathogen identification, is being complemented-and in many cases replaced-by real-time polymerase chain reaction (RT-PCR), nucleic acid amplification tests (NAATs), and loop-mediated isothermal amplification (LAMP) for faster turnaround. These molecular assays enable high sensitivity and specificity, often delivering results within hours compared to the multi-day window required for cultures. Automated blood culture systems with integrated microbial ID and susceptibility profiling are being increasingly adopted for sepsis and bloodstream infection diagnosis. Mass spectrometry platforms, especially matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF), are accelerating organism identification while reducing lab operational costs. Next-generation sequencing (NGS) is emerging as a powerful tool for tracking infection outbreaks and characterizing resistance genes. Additionally, advancements in biosensors, microfluidics, and lab-on-chip technologies are enabling bedside diagnostics with real-time data output. Integration of AI-driven analytics and hospital-wide surveillance platforms is enhancing infection tracking, predictive modeling, and clinical decision support. These innovations are not only improving diagnostic speed and accuracy but also facilitating early isolation and targeted treatment, thereby curbing HAI spread and improving clinical outcomes.

What Healthcare Dynamics and Regulatory Pressures Are Catalyzing Diagnostic Adoption in HAI Control?

The rising prevalence of multidrug-resistant organisms (MDROs), increased use of invasive devices, and an aging population with complex comorbidities are expanding the risk profile for HAIs, intensifying the need for robust diagnostic capabilities. Hospitals are under growing scrutiny from regulatory bodies such as the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and regional health authorities to monitor and report HAI incidence accurately and in real time. Pay-for-performance healthcare models and penalty structures under Medicare and Medicaid Services are incentivizing hospitals to reduce HAI rates or risk financial consequences. Accreditation agencies and infection control standards such as the Joint Commission’s National Patient Safety Goals are reinforcing diagnostic compliance as a core requirement. The COVID-19 pandemic has further highlighted the importance of rapid diagnostics in preventing cross-infection within healthcare settings. Increased healthcare worker awareness and IPC training are also driving demand for integrated diagnostic solutions that support early detection and antimicrobial stewardship. Hospital labs, facing staffing shortages and workload pressures, are investing in automation and high-throughput diagnostic platforms to maintain turnaround times and improve workflow efficiency. These dynamics are converging to make diagnostics an indispensable component of infection control ecosystems within healthcare institutions globally.

What Is Driving the Growth of the Hospital Acquired Infections Diagnostics Market Across Geographies and Use Cases?

The growth in the hospital acquired infections diagnostics market is driven by a combination of rising infection rates, technological innovation, and evolving healthcare accountability standards. High-income countries are investing in advanced molecular and digital diagnostic platforms to meet stringent surveillance requirements and reduce hospital liability. In emerging economies, rapid urbanization, growing healthcare access, and international funding for IPC programs are accelerating the adoption of low-cost, rapid diagnostic tools tailored for resource-limited settings. The expansion of surgical procedures, critical care units, and immunocompromised patient populations-especially in oncology, organ transplantation, and neonatal care-is fueling demand for early and precise HAI diagnostics. The trend toward decentralized diagnostics, point-of-care testing, and home-based care is also creating new application opportunities for compact, automated, and user-friendly diagnostic solutions. Public-private partnerships, favorable reimbursement structures, and government initiatives aimed at combatting antimicrobial resistance are further driving market momentum. These factors collectively are propelling the hospital acquired infections diagnostics market as a vital enabler of safer healthcare delivery, operational excellence, and infection prevention in a rapidly evolving global health landscape.

SCOPE OF STUDY:

The report analyzes the Hospital Acquired Infections Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Consumables, Instruments); Test (Molecular, Conventional); Type (Blood tests, Urinalysis); Infection (UTI, Pneumonia, Surgical site infection, Bloodstream infections, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Abbott Laboratories
  • Bayer AG
  • Beckman Coulter (a Danaher Company)
  • Becton, Dickinson and Company (BD)
  • bioMerieux
  • Bio-Rad Laboratories, Inc.
  • Cepheid (a Danaher Company)
  • Danaher Corporation
  • Ecolab Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenMark Diagnostics (acquired by Roche)
  • Hologic, Inc.
  • Johnson & Johnson
  • Luminex Corporation
  • Merck KGaA
  • Pfizer Inc.
  • QIAGEN N.V.
  • Siemens Healthineers
  • STERIS plc
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Hospital Acquired Infections Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Hospital-Acquired Infections (HAIs) Accelerates Demand for Diagnostic Solutions
    • Technological Advancements in Molecular Diagnostics Expand Addressable Market for HAI Detection
    • Surge in Antimicrobial Resistance (AMR) Threat Strengthens Business Case for Rapid Diagnostic Tools
    • Integration of Artificial Intelligence and Machine Learning in Diagnostics Drives Innovation in HAI Detection
    • Increased Emphasis on Point-of-Care Testing Solutions for HAIs Expands Market Opportunity
    • Rise in Government Initiatives and Funding for Infection Control Drives Adoption of Diagnostic Technologies
    • Regulatory Pressure on Infection Reporting Systems Expands Market for Automated Diagnostic Tools
    • Growing Demand for Real-Time Diagnostic Results Strengthens Opportunities for Advanced Testing Solutions
    • Expansion of Hospital Infrastructure and Healthcare Facilities Increases Need for Robust Infection Diagnostics
    • Technological Integration With Electronic Health Records (EHR) Drives Demand for Seamless Diagnostic Systems
    • Implementation of Infection Control Protocols in Developing Markets Strengthens Global Market Demand
    • Rising Focus on Reducing Healthcare-Associated Costs Drives Adoption of Cost-Effective Diagnostic Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hospital Acquired Infections Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Molecular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Molecular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Molecular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Conventional by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Conventional by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Conventional by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Blood tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Blood tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Blood tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Urinalysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Urinalysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Urinalysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Bloodstream infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Bloodstream infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Bloodstream infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for UTI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for UTI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for UTI by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Pneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Pneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Pneumonia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Surgical site infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Surgical site infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Surgical site infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • JAPAN
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • CHINA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • EUROPE
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • FRANCE
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 101: France Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • GERMANY
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 137: UK Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • INDIA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 212: India Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030
  • AFRICA
    • Hospital Acquired Infections Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Hospital Acquired Infections Diagnostics by Product - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Hospital Acquired Infections Diagnostics by Product - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Hospital Acquired Infections Diagnostics by Test - Molecular and Conventional Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Hospital Acquired Infections Diagnostics by Test - Percentage Breakdown of Value Sales for Molecular and Conventional for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Hospital Acquired Infections Diagnostics by Type - Blood tests and Urinalysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Hospital Acquired Infections Diagnostics by Type - Percentage Breakdown of Value Sales for Blood tests and Urinalysis for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Hospital Acquired Infections Diagnostics by Infection - Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Hospital Acquired Infections Diagnostics by Infection - Percentage Breakdown of Value Sales for Bloodstream infections, Others, UTI, Pneumonia and Surgical site infection for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제